Back to Agenda
Quality Management Post-Quality Management System Implementation In The Wake of ICH E6 (R2)
Session Chair(s)
Jay A Turpen
Head, Quality Assurance, Diligent Pharma LLC, United States
The key characteristics of a QMS with a focus on how the size of an organization impacts the QMS characteristics and their risk-based methodologies, including what key learnings organizations of varying sizes can learn from each other’s experiences.
Learning Objective : Discuss the differing characteristics of a QMS based on the size of the organization; Compare how these characteristics changed in preparation for ICH E6 R2 implementation; Determine whether risk-based approaches vary based on organizational size and what organizations of different sizes can learn from each other.
Speaker(s)
Michael Husovich
Director, Global R&D Quality, Amgen Inc., United States
Assessing Your Clinical Quality Management System: A Comprehensive Review of TransCelerate’s CQMS Assessment Tool
Lenna Kimball, MBA
Vice President, Clinical Operations, Lyell Immunopharma, Inc., United States
Please enter Presentation Title
RJ Doornbos, RPh
Head of Global Quality Systems, Global Quality, Bristol-Myers Squibb Company, United States
Panelist
Have an account?